Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hornedo

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 1997
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancerR García-Carbonero, M Hidalgo, L Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trialC Gomez-Martin, C Solá, J Hornedo, et al.
Leukemia|March 10, 2001
Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamideP Menéndez, F Prósper, C Bueno, et al.
Bone Marrow Transplantation|April 3, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trialJ L Pérez-Gracia, R Colomer, A Ruiz-Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domainR Colomer, A Llombart-Cussac, A Lluch, et al.
Cancer|December 18, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trialJ L Pérez-Gracia, R Colomer, E Esteban, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2006
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropeniaA Jimeno, A Arcediano, S Bazares, et al.
Gynecologic Oncology|August 6, 2008
Novel chemotherapy approaches in chemoradiation protocolsLucía González-Cortijo, N Carballo, A González-Martín, et al.
Journal of the National Cancer Institute|January 4, 2001
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trialR García-Carbonero, J I Mayordomo, M V Tornamira, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 1997
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancerR García-Carbonero, M Hidalgo, L Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trialC Gomez-Martin, C Solá, J Hornedo, et al.
Leukemia|March 10, 2001
Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamideP Menéndez, F Prósper, C Bueno, et al.
Bone Marrow Transplantation|April 3, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trialJ L Pérez-Gracia, R Colomer, A Ruiz-Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domainR Colomer, A Llombart-Cussac, A Lluch, et al.
Cancer|December 18, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trialJ L Pérez-Gracia, R Colomer, E Esteban, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2006
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropeniaA Jimeno, A Arcediano, S Bazares, et al.
Gynecologic Oncology|August 6, 2008
Novel chemotherapy approaches in chemoradiation protocolsLucía González-Cortijo, N Carballo, A González-Martín, et al.
Journal of the National Cancer Institute|January 4, 2001
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trialR García-Carbonero, J I Mayordomo, M V Tornamira, et al.
Pageof 3